Trial Profile
An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs BI 891065 (Primary) ; Ezabenlimab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colon cancer; Gastric cancer; Kidney-neoplasms; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 07 Oct 2021 Status changed from completed to discontinued.
- 04 Nov 2020 Status changed from active, no longer recruiting to completed.
- 07 Sep 2020 Status changed from recruiting to active, no longer recruiting.